Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E8GM
|
||||
| Former ID |
DIB018068
|
||||
| Drug Name |
(+)-LSD
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H25N3O
|
||||
| InChI |
InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18+/m0/s1
|
||||
| InChIKey |
VAYOSLLFUXYJDT-KBXCAEBGSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 7 receptor | Target Info | Agonist | [2] | |
| 5-hydroxytryptamine 2B receptor | Target Info | Agonist | [3] | ||
| 5-hydroxytryptamine 2A receptor | Target Info | Agonist | [3] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Agonist | [4] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway | ||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 7 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 154). | ||||
| REF 2 | Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8547-51. | ||||
| REF 3 | Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. Epub 2004 Jul 30. | ||||
| REF 4 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.